OBJECTIVE: Several methods are utilized for determining the radioiodine activity in the treatment of Graves' disease (hyperthyroidism). Some of this methods do not take into consideration the thyroid absorbed dose or the necessary parameters for this estimation. The association between absorbed dose and administered activity depends on effective half-life, iodine uptake and thyroid mass of each patient. The present study was aimed at developing a methodology for individualized 131I therapy for Graves' disease in patients with hyperthyroidism of the Graves' disease. MATERIALS AND METHODS: A neck-thyroid phantom developed at Instituto de Radioproteção e Dosimetria, containing a standard solution of 131I, was utilized for calibrating the scintillation gamma camera and uptake probe installed in the Department of Nuclear Medicine of the Hospital Universitário Clementino Fraga Filho da Universidade Federal do Rio de Janeiro. RESULTS: The view angle of the collimator/detector assembly presented values compatible with the thyroid gland size for distances of 25 cm (uptake probe) and 45.8 cm (scintillation gamma camera). Calibration factors were 39.3 ± 0.78 and 4.3 ± 0.17 cpm/kBq, respectively. The 14-30-hour interval in the retention curve allows the estimation of activity between two points for determining the effective iodine half-life in the thyroid. CONCLUSION: The utilization of equipment usually available in nuclear medicine clinics is feasible, so this is a simple, effective and low cost methodology.
Graves' disease; Hyperthyroidism; Iodine therapy; Iodine-131; Scintillation gamma camera; Uptake probe
